XTNT Quote, Financials, Valuation and Earnings

InfuSystems Holdings has a net margin of -17.98% compared to Xtant Medical Holdings's net margin of 5.12%. Xtant Medical Holdings's return on equity of -35.98% beat InfuSystems Holdings's return on equity of 2.8%.

Xtant Medical Holdings has a consensus price target of --, signalling upside risk potential of 469.04%. On the other hand InfuSystems Holdings has an analysts' consensus of -- which suggests that it could grow by 72.05%. Given that Xtant Medical Holdings has higher upside potential than InfuSystems Holdings, analysts believe Xtant Medical Holdings is more attractive than InfuSystems Holdings.

Xtant Medical Holdings has a beta of 0.357, which suggesting that the stock is 64.342% less volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.528, suggesting its more volatile than the S&P 500 by 52.819%.

Xtant Medical Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xtant Medical Holdings pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

Xtant Medical Holdings quarterly revenues are $27.9M, which are smaller than InfuSystems Holdings quarterly revenues of $35.3M. Xtant Medical Holdings's net income of -$5M is lower than InfuSystems Holdings's net income of $1.8M. Notably, Xtant Medical Holdings's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 129.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xtant Medical Holdings is 0.46x versus 1.33x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of -17.98% compared to Xtant Medical Holdings's net margin of --. Xtant Medical Holdings's return on equity of -35.98% beat Plus Therapeutics's return on equity of --.

Xtant Medical Holdings has a consensus price target of --, signalling upside risk potential of 469.04%. On the other hand Plus Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1358.33%. Given that Plus Therapeutics has higher upside potential than Xtant Medical Holdings, analysts believe Plus Therapeutics is more attractive than Xtant Medical Holdings.

Xtant Medical Holdings has a beta of 0.357, which suggesting that the stock is 64.342% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.705, suggesting its less volatile than the S&P 500 by 29.519%.

Xtant Medical Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xtant Medical Holdings pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

Xtant Medical Holdings quarterly revenues are $27.9M, which are larger than Plus Therapeutics quarterly revenues of --. Xtant Medical Holdings's net income of -$5M is lower than Plus Therapeutics's net income of -$2.9M. Notably, Xtant Medical Holdings's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xtant Medical Holdings is 0.46x versus 1.18x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -17.98% compared to Xtant Medical Holdings's net margin of -18.58%. Xtant Medical Holdings's return on equity of -35.98% beat Retractable Technologies's return on equity of -16.83%.

Xtant Medical Holdings has a consensus price target of --, signalling upside risk potential of 469.04%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Xtant Medical Holdings has higher upside potential than Retractable Technologies, analysts believe Xtant Medical Holdings is more attractive than Retractable Technologies.

Xtant Medical Holdings has a beta of 0.357, which suggesting that the stock is 64.342% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

Xtant Medical Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xtant Medical Holdings pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

Xtant Medical Holdings quarterly revenues are $27.9M, which are larger than Retractable Technologies quarterly revenues of $10.3M. Xtant Medical Holdings's net income of -$5M is lower than Retractable Technologies's net income of -$1.9M. Notably, Xtant Medical Holdings's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xtant Medical Holdings is 0.46x versus 0.50x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -17.98% compared to Xtant Medical Holdings's net margin of -4291.67%. Xtant Medical Holdings's return on equity of -35.98% beat Catheter Precision's return on equity of -65.84%.

Xtant Medical Holdings has a consensus price target of --, signalling upside risk potential of 469.04%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 429.24%. Given that Xtant Medical Holdings has higher upside potential than Catheter Precision, analysts believe Xtant Medical Holdings is more attractive than Catheter Precision.

Xtant Medical Holdings has a beta of 0.357, which suggesting that the stock is 64.342% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

Xtant Medical Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xtant Medical Holdings pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Xtant Medical Holdings quarterly revenues are $27.9M, which are larger than Catheter Precision quarterly revenues of $96K. Xtant Medical Holdings's net income of -$5M is lower than Catheter Precision's net income of -$4.1M. Notably, Xtant Medical Holdings's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xtant Medical Holdings is 0.46x versus 1.01x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.